Co-Trimoxazole Induced Severe Cutaneous Adverse Reaction: A Challenging Diagnosis

INTRODUCTION

Drug Reaction with Eosinophilia and systemic symptoms (DRESS) Syndrome is a life-threatening reaction with a mortality rate of 10-20%. Clinical handling of adverse drug reaction (ADR) is difficult, especially in HIV as some ADRs get potentiated with other drugs.

Trimethoprim-Sulfamethoxazole (TMP-SMX) is accountable for 40-80% ADR in HIV patients compared to 3-5% in the general population. Anti-tuberculor drugs are also well known instigators of the syndrome. Still, the lack of a gold standard for its diagnosis makes it difficult and clinical judgement is paramount. The reaction shares clinical characteristics with other dermatologic conditions, mandating the physicians to closely investigate to attain a rightful diagnosis. It is still challenging to identify the culprit drug among the pool.

We present a case of late presentation and diagnosis of TMP-SMX induced DRESS in an HIV patient.

CASE PRESENTATION

A 51-year-old male patient with a BMI of 14.33kg/m² and with a known history of Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) visited the hospital on 11th February 2020 with complaints of generalised scaling and redness, which aggravated since 5 days. The reaction was started 45 days back and was prescribed with liquid paraffin suspecting it as HIV associated dermatitis from a local hospital. Significant improvement was seen with steroid, antihistamines and other topical agents.

The symptoms started 45 days ago and were noticed across the body except soles and lower zone. He also had mild facial and pedal oedema. He furthermore complained of red and watery eyes.

On initial examination, the patient was found to be as long as 105 days after the first intake of the drug, rather than the usual presentation period of 2-6 week.

On admission, the patient was afebrile (99.1°F), with 100/60mmHg BP, 96 mmHg Oxygen saturation, 100/60mmHg and 100% SPO2. The patient showed bony marrow and liver enzymes (SGPT 164 U/L). Chest X-ray showed bilateral opacities predominantly in the left lower zone. Dermatologist ruled other skin disorders including Psoriasis and he agreed with the physician’s suspicion of a drug reaction.
In view of patient’s symptoms, hepatic involvement, clinician’s judgement and a "Possible" score in RegiSCAR (Table 1), DRESS syndrome was confirmed.

**Figure 1: Patient on Day 1**

<table>
<thead>
<tr>
<th>REGI SCAR SCALE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever &gt;38.5°Celsius</td>
<td>0</td>
</tr>
<tr>
<td>Enlarged lymph node (&gt;2 sites, &gt;1 cm)</td>
<td>0</td>
</tr>
<tr>
<td>Atypical lymphocytes</td>
<td>0</td>
</tr>
<tr>
<td>Eosinophilia</td>
<td>2</td>
</tr>
<tr>
<td>700-1499 or 10% - 19.9%</td>
<td></td>
</tr>
<tr>
<td>Skin rash</td>
<td>1</td>
</tr>
<tr>
<td>Extent &gt; 50%</td>
<td>1</td>
</tr>
<tr>
<td>At least 2:</td>
<td></td>
</tr>
<tr>
<td>Edema, infiltration, purpura, scaling</td>
<td></td>
</tr>
<tr>
<td>Biopsy suggesting DRESS</td>
<td>0</td>
</tr>
<tr>
<td>Internal organ involvement</td>
<td></td>
</tr>
<tr>
<td>One</td>
<td>1</td>
</tr>
<tr>
<td>Two or more</td>
<td></td>
</tr>
<tr>
<td>Evaluation of other potential causes (anti-nuclear antibody, blood culture, serology for HAV/HBV/HCV, Chlamydia/ Mycoplasma)</td>
<td>0</td>
</tr>
<tr>
<td>If none of these positive and &gt;3 are negative</td>
<td></td>
</tr>
<tr>
<td>&lt;2 : No case , 2-3 : Possible , 4-5 : Probable , &gt;5 : Definite</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1: RegiSCAR Score**

With a personal interview, patient’s medication history was found to be as follows:
ATT (Continuation phase) - Isoniazid, Rifampicin, ethambutol- started on 21st September 2019.
ART - Tenofovir, Lamivudine, and Efavirenz- started on 22nd October 2019. And
Antibiotic - Trimethoprim-Sulfamethoxazole (TMP-SMX) - started on 22nd October 2019.
All the drugs except ART was withdrawn on the Day of admission and symptomatic treatment was given with Steroids, Antihistamines and nutritional supplements.

On day 7, Isoniazid 450mg OD and Ethambutol 800mg OD were rechallenged uneventfully. Rifampicin 300mg OD was reintroduced on Day 10, and on absense of symptoms it was titrated to 600mg OD on Day 13. Patient tolerated well and was symptomatically improved. Meanwhile steroid tapering was initiated (Table 2). Co-trimoxazole was not rechallenged as the physician suspected it and rifampicin the most. On assessing causality using Naranjo Scale; association was found Probable for Co-trimoxazole.

He got discharged on Day 16 with prednisolone, antihistamines and other topical agents.

Table 2: Steroids Prescribed.

<table>
<thead>
<tr>
<th>Sl No</th>
<th>Steroid</th>
<th>Dose</th>
<th>Route</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Inj Dexamethasone</td>
<td>8mg-0-4 mg</td>
<td>IV</td>
<td>Day 0,1,2</td>
</tr>
<tr>
<td>2</td>
<td>Inj Dexamethasone</td>
<td>8mg-0-0</td>
<td>IV</td>
<td>Day 3,4,5</td>
</tr>
<tr>
<td>3</td>
<td>Inj Dexamethasone</td>
<td>4.5mg-0-0</td>
<td>IV</td>
<td>Day 6,7,8</td>
</tr>
<tr>
<td>4</td>
<td>Tab Prednisolone</td>
<td>30mg-0-0</td>
<td>PO</td>
<td>Day 9,10,11</td>
</tr>
<tr>
<td>5</td>
<td>Tab Prednisolone</td>
<td>20mg-0-0</td>
<td>PO</td>
<td>Day 12,13,14</td>
</tr>
<tr>
<td>6</td>
<td>Tab Prednisolone</td>
<td>10mg-0-0</td>
<td>PO</td>
<td>Day 15,16,17</td>
</tr>
</tbody>
</table>

DISCUSSION

DRESS Syndrome is a severe Type IV (Delayed type) hypersensitivity reaction commonly seen in HIV patients. But multiple co-morbidities and co-infections make it challenging for prompt diagnosis and cessation of the culprit drug. In our case, the patient had a mild cutaneous reaction for about 1 and half months but was misdiagnosed with HIV associated exfoliative dermatitis. Due to the non-specific clinical features, DRESS syndrome mimics many other conditions considerably affecting the prognosis. The signs of fever, skin and organ involvement in DRESS, often led to speculate infectious disease as the primary diagnosis. The suspicion to DRESS curtails after the usual reaction period of 2-6 week as discerned in our case. But it must be duly noted that the latency period can be as long as 105 days after the first intake of drug.

RegiSCAR is primarily used to attain the diagnosis of DRESS. According to RegiSCAR scoring system, features of DRESS include fever, eosinophilia, lymphadenopathy, atypical lymphocytes, skin rash, visceral organ involvement, and duration of disease more than fifteen days. But it was observed that, patients defined as “no/possible cases” by the scoring system accounted for almost one-quarter of all the reported DRESS cases. This can lead to misdiagnosis, thereby increasing morbidity and mortality.

An important concern to work out was to identify the source of reaction from the multiple drugs. Hence all the suspected drugs were withdrawn and the least suspected and most essential ones for the patient were restarted at a lower dose with caution. A decision not to rechallenge TMP-SMX was taken in our case, as it wasn’t essential and to avoid severe consequences as our team highly suspected it as the cause. Even though steroid treatment in DRESS results in a substantial improvement, consensus are lacking regarding the choice, dose and duration of steroids. Further researches are necessary to propose specific diagnostic and treatment protocols for the syndrome.

CONCLUSION:

Although drug reaction is common in HIV, due to clinical similarities with other skin conditions it is often misdiagnosed. We present this case so that the DRESS syndrome should be considered in patients with a cutaneous reaction among other differential diagnoses even after the
usual presentation period of 2 to 6 weeks. The latency period of DRESS can be as long as 105 days. A rightful diagnosis of DRESS requires a physician with high degree of suspicion to exclude the mimickers.

**Sources of Support:** Nil

**Conflicting Interest:** Nil

**REFERENCES**


